200 related articles for article (PubMed ID: 29020849)
41. In vivo study of doxorubicin-loaded cell-penetrating peptide-modified pH-sensitive liposomes: biocompatibility, bio-distribution, and pharmacodynamics in BALB/c nude mice bearing human breast tumors.
Ding Y; Cui W; Sun D; Wang GL; Hei Y; Meng S; Chen JH; Xie Y; Wang ZQ
Drug Des Devel Ther; 2017; 11():3105-3117. PubMed ID: 29123382
[TBL] [Abstract][Full Text] [Related]
42. Production of limit size nanoliposomal systems with potential utility as ultra-small drug delivery agents.
Zhigaltsev IV; Tam YK; Leung AK; Cullis PR
J Liposome Res; 2016; 26(2):96-102. PubMed ID: 25856305
[TBL] [Abstract][Full Text] [Related]
43. Liposomes for targeting hepatocellular carcinoma: use of conjugated arabinogalactan as targeting ligand.
Shah SM; Goel PN; Jain AS; Pathak PO; Padhye SG; Govindarajan S; Ghosh SS; Chaudhari PR; Gude RP; Gopal V; Nagarsenker MS
Int J Pharm; 2014 Dec; 477(1-2):128-39. PubMed ID: 25311181
[TBL] [Abstract][Full Text] [Related]
44. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model.
Moosavian SA; Abnous K; Badiee A; Jaafari MR
Colloids Surf B Biointerfaces; 2016 Mar; 139():228-36. PubMed ID: 26722819
[TBL] [Abstract][Full Text] [Related]
45. Microfluidic-assisted fabrication of phosphatidylcholine-based liposomes for controlled drug delivery of chemotherapeutics.
Gkionis L; Aojula H; Harris LK; Tirella A
Int J Pharm; 2021 Jul; 604():120711. PubMed ID: 34015381
[TBL] [Abstract][Full Text] [Related]
46. Lactoferrin-modified PEGylated liposomes loaded with doxorubicin for targeting delivery to hepatocellular carcinoma.
Wei M; Guo X; Tu L; Zou Q; Li Q; Tang C; Chen B; Xu Y; Wu C
Int J Nanomedicine; 2015; 10():5123-37. PubMed ID: 26316745
[TBL] [Abstract][Full Text] [Related]
47. LyP-1-conjugated PEGylated liposomes: a carrier system for targeted therapy of lymphatic metastatic tumor.
Yan Z; Wang F; Wen Z; Zhan C; Feng L; Liu Y; Wei X; Xie C; Lu W
J Control Release; 2012 Jan; 157(1):118-25. PubMed ID: 21827801
[TBL] [Abstract][Full Text] [Related]
48. Two cholesterol derivative-based PEGylated liposomes as drug delivery system, study on pharmacokinetics and drug delivery to retina.
Geng S; Yang B; Wang G; Qin G; Wada S; Wang JY
Nanotechnology; 2014 Jul; 25(27):275103. PubMed ID: 24960297
[TBL] [Abstract][Full Text] [Related]
49. Membrane-Loaded Doxorubicin Liposomes Based on Ion-Pairing Technology with High Drug Loading and pH-Responsive Property.
Xu H; Zhang L; Li L; Liu Y; Chao Y; Liu X; Jin Z; Chen Y; Tang X; He H; Kan Q; Cai C
AAPS PharmSciTech; 2017 Aug; 18(6):2120-2130. PubMed ID: 28028795
[TBL] [Abstract][Full Text] [Related]
50. Liposome Delivery Systems for Inhalation: A Critical Review Highlighting Formulation Issues and Anticancer Applications.
Rudokas M; Najlah M; Alhnan MA; Elhissi A
Med Princ Pract; 2016; 25 Suppl 2(Suppl 2):60-72. PubMed ID: 26938856
[TBL] [Abstract][Full Text] [Related]
51. Enhanced retention and anti-tumor efficacy of liposomes by changing their cellular uptake and pharmacokinetics behavior.
Li Y; Liu R; Yang J; Shi Y; Ma G; Zhang Z; Zhang X
Biomaterials; 2015 Feb; 41():1-14. PubMed ID: 25522960
[TBL] [Abstract][Full Text] [Related]
52. Liposome formulation of a novel hydrophobic aryl-imidazole compound for anti-cancer therapy.
Liu J; Lee H; Huesca M; Young A; Allen C
Cancer Chemother Pharmacol; 2006 Sep; 58(3):306-18. PubMed ID: 16333677
[TBL] [Abstract][Full Text] [Related]
53. Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity.
Jung SH; Jung SH; Seong H; Cho SH; Jeong KS; Shin BC
Int J Pharm; 2009 Dec; 382(1-2):254-61. PubMed ID: 19666094
[TBL] [Abstract][Full Text] [Related]
54. Conventional vs PEGylated loaded liposomal formulations by microfluidics for delivering hydrophilic chemotherapy.
Jaradat E; Meziane A; Lamprou DA
Int J Pharm; 2024 Apr; 655():124077. PubMed ID: 38569975
[TBL] [Abstract][Full Text] [Related]
55. Effects of lipid composition on the properties of doxorubicin-loaded liposomes.
Sakai-Kato K; Nanjo K; Kawanishi T; Okuda H; Goda Y
Ther Deliv; 2015 Jul; 6(7):785-94. PubMed ID: 26228772
[TBL] [Abstract][Full Text] [Related]
56. Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomes.
Gabizon AA; Tzemach D; Horowitz AT; Shmeeda H; Yeh J; Zalipsky S
Clin Cancer Res; 2006 Mar; 12(6):1913-20. PubMed ID: 16551877
[TBL] [Abstract][Full Text] [Related]
57. Biodistribution of ascorbyl palmitate loaded doxorubicin pegylated liposomes in solid tumor bearing mice.
Jukanti R; Devraj G; Shashank AS; Devraj R
J Microencapsul; 2011; 28(2):142-9. PubMed ID: 21265713
[TBL] [Abstract][Full Text] [Related]
58. Anti-neuropilin 1 antibody Fab' fragment conjugated liposomal docetaxel for active targeting of tumours.
Manjappa AS; Goel PN; Gude RP; Ramachandra Murthy RS
J Drug Target; 2014 Sep; 22(8):698-711. PubMed ID: 24766186
[TBL] [Abstract][Full Text] [Related]
59. Novel microfluidic swirl mixers for scalable formulation of curcumin loaded liposomes for cancer therapy.
Xu R; Tomeh MA; Ye S; Zhang P; Lv S; You R; Wang N; Zhao X
Int J Pharm; 2022 Jun; 622():121857. PubMed ID: 35623489
[TBL] [Abstract][Full Text] [Related]
60. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies.
Gabizon A; Shmeeda H; Barenholz Y
Clin Pharmacokinet; 2003; 42(5):419-36. PubMed ID: 12739982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
